OutSee lands $68K grant to automate drug target validation with agentic AI

What's the deal? OutSeeDealroom has a profile for this one. Try Dealroom →, a Cambridge-based genomics and drug discovery company, has been awarded a £50,000 (about $68,000) grant to build a prototype agentic AI system for validating drug targets. The funding comes jointly from Innovate UKDealroom has a profile for this one. Try Dealroom → and Empirical VenturesDealroom has a profile for this one. Try Dealroom →, through Innovate UK's Investor Partnership grant programme.

What's the endgame? OutSee's core platform, NomalyDealroom has a profile for this one. Try Dealroom →, uses an AI-driven biological engine to identify new therapeutic targets from small or previously analysed datasets. The grant funds a pilot study for a sub-system that would triage Nomaly's output automatically — a step now done manually by the company's scientific team.

Why now? Target validation is a bottleneck. Automating the initial screening would let scientists focus on the targets with the strongest case for therapeutic development.

"By building agentic AI into our validation pipeline, we will maximise the impact of our exceptional target discovery scientists and accelerate discovery of high-quality novel targets," said Julian Gough, chief executive officer and founder.

OutSee runs an in-house discovery pipeline focused on neurology, rare, and metabolic diseases, including a Longitude Prize on ALS-funded project targeting ALS. It also partners with o2h DiscoveryDealroom has a profile for this one. Try Dealroom → on a drug discovery programme using its lead target asset.

The signal: The round is a small one — landing in the bottom fifth of deals by size. But the pairing of a public agency with a venture investor points to a familiar pattern in early-stage UK biotech: modest, matched grants used to de-risk a specific technical step before larger capital follows.

Read more: cambridgenetwork.co.uk

Image credit: Centers for Disease Control and Prevention